Back

Correlations of 276 missense variants of PSEN1, PSEN2, and APP on the production of Aβ peptides against variant effect predictors and biophysical structures

Song, J.; Yan, S.; Liu, S.; Sridhar, A.; Sung, K.; Pillai, J.; Wu, C.

2026-02-11 neuroscience
10.64898/2026.02.10.705105 bioRxiv
Show abstract

INTRODUCTIONEarly-onset Alzheimers disease (EOAD) is mostly caused by mutations in Presenilin-1,2 (PSEN1, PSEN2), and amyloid precursor protein (APP) genes. Both genetic and experimental evidence has supported the PSEN-APP amyloid hypothesis as the leading pathogenesis of AD. Thus far, 276 missense variants from PSEN1,2, and APP have been identified. Herein, we report the development of algorithm platforms for predicting the degrees of pathogenic potentials of these various missense mutations in AD. METHODSWe performed extensive pairwise correlations between 276 in vitro functional assays of missense variants from PSEN1, PSEN2, and APP and clinical data among EOAD patients against 37 variant effect predictors (VEPs). Furthermore, we used the structural models of all three proteins to refine understanding of the molecular basis of missense variants in dominant negative (DN) or loss-of-function (LoF) effects. RESULTSWe found that VEPs were consistently correlated with age of onset (AAO) among EOAD patients and the A{beta}42/A{beta}40 ratio biomarker. This study also identified discrepancies in the predictor variable leading to an increase in the A{beta}42/A{beta}40 ratio; The increased A{beta}42/A{beta}40 ratio was due to decreased A{beta}40 levels by Sun et al., (2016), while Petit et al., (2022) argued that increased A{beta}42 level was the culprit. We also identified that with increased predicted pathogenicity, there were decreased A{beta}38 levels. Conversely, this study found no direct correlations with A{beta}37 and A{beta}43. Lastly, structural studies show characteristics of either DN and LoF mechanisms, as there were numerous variants located in buried hydrophobic domains and those on charged surfaces of the proteins. DISCUSSIONCurrently, a major limitation in the field is the lack of reliable approaches for predicting the pathogenicity of variants in EOAD. We show that VEPs are promising in deciphering the effects of variants in PSEN1, PSEN2, and APP genes, especially between multiple pathogenic mutations. Our study also illuminates the need for experimental studies to identify the predictor variable causing the increased A{beta}42/A{beta}40 biomarker. Our biophysical studies also identify the need to characterize whether the mechanism of pathogenesis caused by DN or LoF effects is in scope of the presenilin hypothesis. Research in ContextO_LISystematic review: The authors reviewed experimental evidence of pathogenic PSEN1, PSEN2, and APP variants in scope of the presenilin hypothesis. To our knowledge, the pathogenesis of EOAD remains incompletely understood. There are also no predictive tools/models available for informing clinical translation. C_LIO_LIInterpretation: VEPs demonstrate strong correlations with AAO and A{beta} levels from pairwise correlations with 276 missense variants. Structurally, it appears that mutations demonstrate characteristics of dominant negative and loss-of-function effects. C_LIO_LIFuture Direction: Larger studies are necessary of VEPs for realistic clinical usage. C_LI HighlightsO_LIWe performed correlations of 37 VEPs against in vitro data of EOAD variants. C_LIO_LIVEPs demonstrate potential as diagnostic tools for early onset Alzheimers disease. C_LIO_LIPathogenic missense variants show characteristics of DN and LoF effects. C_LI

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
Journal of Alzheimer's Disease
43 papers in training set
Top 0.1%
10.4%
2
Frontiers in Aging Neuroscience
67 papers in training set
Top 0.3%
8.7%
3
Alzheimer's Research & Therapy
52 papers in training set
Top 0.4%
5.0%
4
Alzheimer's & Dementia: Translational Research & Clinical Interventions
16 papers in training set
Top 0.1%
5.0%
5
PLOS ONE
4510 papers in training set
Top 30%
5.0%
6
Scientific Reports
3102 papers in training set
Top 26%
4.4%
7
Journal of Alzheimer’s Disease
39 papers in training set
Top 0.2%
4.1%
8
Neurobiology of Aging
95 papers in training set
Top 0.7%
4.1%
9
Alzheimer's & Dementia
143 papers in training set
Top 1%
3.7%
50% of probability mass above
10
International Journal of Molecular Sciences
453 papers in training set
Top 4%
2.8%
11
Frontiers in Neuroscience
223 papers in training set
Top 2%
2.7%
12
Neurobiology of Disease
134 papers in training set
Top 2%
2.1%
13
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
38 papers in training set
Top 0.6%
1.9%
14
Brain Communications
147 papers in training set
Top 2%
1.5%
15
PLOS Computational Biology
1633 papers in training set
Top 18%
1.4%
16
Neuropathology and Applied Neurobiology
14 papers in training set
Top 0.3%
1.4%
17
GeroScience
97 papers in training set
Top 1%
1.4%
18
Journal of Proteome Research
215 papers in training set
Top 1%
1.3%
19
ACS Chemical Neuroscience
60 papers in training set
Top 2%
1.0%
20
Translational Psychiatry
219 papers in training set
Top 3%
1.0%
21
Frontiers in Molecular Biosciences
100 papers in training set
Top 4%
0.8%
22
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
25 papers in training set
Top 0.7%
0.8%
23
eLife
5422 papers in training set
Top 55%
0.8%
24
International Journal of Neuropsychopharmacology
11 papers in training set
Top 0.2%
0.8%
25
The Journal of Prevention of Alzheimer's Disease
10 papers in training set
Top 0.3%
0.8%
26
Biomedicines
66 papers in training set
Top 3%
0.8%
27
Frontiers in Neuroinformatics
38 papers in training set
Top 0.8%
0.7%
28
Molecular Brain
26 papers in training set
Top 0.3%
0.7%
29
eneuro
389 papers in training set
Top 10%
0.7%
30
ACS Omega
90 papers in training set
Top 5%
0.7%